Posted by Michael Wonder on 19 May 2022
EMA accepts filing of marketing authorisation application for Valneva’s inactivated COVID-19 vaccine candidate
19 May 2022 - 2022 – Valneva today confirmed that the EMA has accepted the filing of a marketing authorisation application for Valneva’s inactivated, whole-virus COVID-19 vaccine candidate, VLA2001.
If the CHMP accepts Valneva’s conditional marketing authorisation application, the Company confirms it would expect to receive a positive CHMP opinion in June 2022.
